Answers are grounded in this paper and cite their sources.
Investigates a DNA vaccine's effect on tumor immunity, demonstrating significant E7-specific T-cell responses in mice, suggesting its potential in cancer treatment.
Calreticulin (CRT) is an endoplasmic reticulum chaperone that facilitates antigen processing and presentation, making it an attractive fusion partner for enhancing tumor-specific T-cell responses in DNA vaccine development. However, the relative efficacy of CRT compared with other antigen-presentation–enhancing strategies has not been fully evaluated. We constructed a DNA vaccine encoding the immunodominant human papillomavirus (HPV)-16 E7 minigene epitope (aa 49–57) fused to the C-terminus of CRT (pcDNA3-CRT-E7(49–57), hereafter CRT-E7(49–57)). This vaccine was compared with DNA vaccines encoding CRT linked to full-length E7 (CRT-E7(1–98)) and other antigen-presentation–enhancing constructs, including ubiquitin linked to E7 minigene (Ub-E7(49–57)) and MHC class I trafficking domain linked to E7 minigene (MITD-E7 (49–57)). We evaluated E7-specific cytotoxic T-cell responses, tumor volume, and survival in both prophylactic and therapeutic TC-1 tumor models. Intramuscular electroporation of C57BL/6 mice with CRT-E7(49–57) elicited robust E7-specific CD8⁺ T-cell responses comparable to those induced by CRT-E7(1–98) and MITD-E7(49–57), but higher than those elicited by Ub-E7 (49–57). CRT-E7(49–57) vaccination provided complete protection against TC-1 tumor challenge, with mice remaining tumor-free and surviving beyond 60 days. Vaccinated mice also exhibited strong immune memory, as tumor rechallenge triggered potent E7-specific CD8⁺ T-cell responses and restricted tumor growth. In therapeutic settings, two doses of CRT-E7(49–57) completely suppressed tumor progression, outperforming Ub-E7(49–57) and conferring superior survival compared with MITD-E7(49–57). The CRT-E7(49–57) DNA vaccine induces durable, high-magnitude E7-specific CD8⁺ T-cell responses and confers effective prophylactic and therapeutic antitumor immunity, underscoring its promise as a versatile platform for cancer immunotherapy.
No takes yet. Share an insight, caveat, or question.
Chang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: